Perspective Income Tax Expense from 2010 to 2024

CATX Stock   3.45  0.20  5.48%   
Perspective Therapeutics Income Tax Expense yearly trend continues to be fairly stable with very little volatility. Income Tax Expense is likely to outpace its year average in 2024. During the period from 2010 to 2024, Perspective Therapeutics Income Tax Expense regression line of annual values had significance of  0.02 and arithmetic mean of (421,058). View All Fundamentals
 
Income Tax Expense  
First Reported
1999-03-31
Previous Quarter
7.8 M
Current Value
-61 K
Quarterly Volatility
1.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Perspective Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Perspective Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Total Revenue of 1.4 M or Gross Profit of 1.3 M, as well as many indicators such as Price To Sales Ratio of 55.63, Dividend Yield of 0.0 or PTB Ratio of 1.36. Perspective financial statements analysis is a perfect complement when working with Perspective Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Perspective Therapeutics Correlation against competitors.
For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.

Latest Perspective Therapeutics' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Perspective Therapeutics over the last few years. It is Perspective Therapeutics' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Perspective Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Slightly volatile
   Income Tax Expense   
       Timeline  

Perspective Income Tax Expense Regression Statistics

Arithmetic Mean(421,058)
Coefficient Of Variation(232.65)
Mean Deviation608,188
Median(177,000)
Standard Deviation979,613
Sample Variance959.6B
Range4M
R-Value(0.59)
Mean Square Error673.7B
R-Squared0.35
Significance0.02
Slope(129,240)
Total Sum of Squares13.4T

Perspective Income Tax Expense History

2024-2.5 M
2023-2.7 M
2021-119 K
2020-199 K
2019-177 K
2018-294 K
2017-145 K

About Perspective Therapeutics Financial Statements

Perspective Therapeutics investors use historical fundamental indicators, such as Perspective Therapeutics' Income Tax Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Perspective Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense-2.7 M-2.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Perspective Stock Analysis

When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.